Contact Us

Sibelius News, Events & Articles

1 August 2013 
Sibelius Signs Contract with Creeyan
Sibelius signs contract with Creeyan Laboratories, Malaysia, to utilise the ChronoscreenTM to analyse lead product -Immuno-IBG.
Read+
30 July 2013 
Type II Diabetes Mellitus Screening
Sibelius embarks upon Type II Diabetes Mellitus (T2DM) screening combining patent pending screening technology with bespoke genetic array.
Read+
18 February 2013 
Development of Third Proprietary Product
Sibelius has begun development of its third proprietary nutraceutical product. 
Read+
14 January 2013 
High Through-Put Mechanism of Action Screening
Sibelius has completed a final report on the Mechanism of Action (MOA) of an active anti-ageing compound from a world leading […]
Read+
10 October 2012 
Novel Proprietary Anti-Ageing Compound Discovered
Sibelius has identified a highly potent anti-ageing compound and is now commencing combination screening with this compound to seek out […]
Read+
17 September 2012 
Development of Second Proprietary Product
Following successful identification of active compounds Sibelius is preparing the development of its second proprietary nutraceutical product.
Read+
Load more
Search
Categories
Subscribe to Our Newsletter
Keep up to date with the latest insights
news, events, developments and
product launches
Newsletter Subscribe

How can we help you?

Please fill in the form below and a member of the team will get back to you. To read our privacy policy, click here.
How can we help?
crossmenu